Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) is being beaten hard this morning. News hit that the FDA has now rejected the company’s Northera drug to treat low blood pressure for now in a complete response. Effectively the FDA is asking Chelsea to provide more efficacy data.
Sadly, this could actually create a one or two year delay and the company was worth only $246 million before the news impact. Chelsea has said that it still needs to have discussions with the FDA so that it can satisfy the FDA’s request.
The company believes that an ongoing trial might meet the FDA’s criteria but it is not sure if the FDA will require changes to the primary endpoint of Northera. Unfortunately this is still just unfinished business.
Investors are shooting first and asking questions later. Shares are down 28% at $2.62 in pre-market trading and the 52-week trading range is $2.18 to $6.06. The NASDAQ pre-market trading alert has already gone over 800,000 shares and it is worth noting that the most recent short interest was at a yearly high of 7.26 million shares as of the March 15 settlement date.
The company is pre-revenue and it had about $45 million in liquidity at the end of the 2011 year.
JON C. OGG
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.